The latest obesity drug to be evaluated in clinical trials, retatrutide (a GLP-1, GIP and glucagon triple receptor agonist), has only recently undergone phase-two studies for type 2 diabetes [54] and obesity [4], without a lifestyle intervention component in either study. Here, GLP1R is linked to obesity disorder.